Raj Nagarkar

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Beth Y. Karlan, Amit M. Oza, Gary Richardson et al. · Journal of Clinical Oncology · 2011 · 226 citations · Full text

Medicine, Oncology, Pharmacology +17

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

Denis Soulières, Sandrine Faivre, Éva Remenár et al. · The Lancet Oncology · 2017 · 219 citations

Medicine, Oncology, Pharmacotherapy +11

Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

R. C. Newton, E C Bradley, Richard S. Levy et al. · Journal of Clinical Oncology · 2010 · 45 citations

Medicine, Oncology, Pharmacology +17

Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients.

Steven Friedman, Richard Levy, William M. Garrett et al. · Cancer Research · 2009 · 37 citations

Medicine, Oncology, Pharmacology +17

Hepatocellular carcinoma with uncommon sites of metastasis: a rare case report

Mangala Targe, Raj Nagarkar · The Egyptian Journal of Radiology and Nuclear Medicine · 2021 · 20 citations · Full text

Medicine, Oncology, Radiology +17